Articles

Increasingly, biopharma research & development experimental data are siloed and stored in varying formats. This makes it difficult to search, retrieve and share data. Furthermore, these data are often not interoperable, making it impossible to compare. Data needs to be better managed to be more collaborative, shareable, and interoperable, in order to accelerate research and continue making breakthroughs. Data standardization aims to forge a path toward machine-readable and actionable data that can be found, accessed, and reused with minimal human intervention.

Presented here are some tips to help you avoid buyer’s remorse and make an educated decision about which instrument to purchase. These tips provide you with the tools to make an informed decision when purchasing a cell sorter.

Coming soon: The next iteration in Bio-Rad’s tradition of qPCR excellence. The compact CFX Opus Real-Time PCR System is more connected, consistent, and easier to use than ever before, and is available in 96- and 384-well formats. The CFX Opus Systems launch with our new BR.io cloud platform and the latest version of CFX Maestro Software, for complete instrument control and data analysis capabilities.

Fluorescence-activated cell sorting is a valuable tool for research, but could the physical forces of sorting stress the cells, altering their behavior and confounding experimental results? Recent research found that although cell sorting activated p38 MAPK stress signaling, no functional or structural changes were observable. The results indicate that jet-in-air systems such as the Bio-Rad S3e Cell Sorter do not alter cell behavior.

As phase 3 clinical trials of investigational vaccines for COVID-19 begin in the U.S., you may be wondering what it takes to make an effective vaccine? In case you missed it, check out our Hanging with My Chromies podcast, episodes 6 and 10 on vaccine development and viral spread, and learn about the role chromatography plays in making a successful vaccine.

Incorporating fluorescence-based cell sorting into your lab grants you powerful access to new research areas and rarer cell types without sacrificing efficiency or results. New, powerful techniques like CRISPR and single-cell analysis are enhanced by the isolation of specific cells. But isolating cell populations of the right quality and quantity is both challenging and time consuming. We offer some tips to set yourself up for success and get the most out of your sorts.

The Human Genome Project was completed nearly two decades ago, in 2003. The primary vision of this project was to produce a human reference genome, a representative example of the set of genes in one idealized individual human. However, the currently available reference genomes do not represent the genetic diversity found across different human populations. As such, any downstream products (drugs therapies, personalized medicine, etc.) derived from the human genome will not accurately represent the vast majority of the human population.

Presented by: Matthew L. Turner, PhD, Field Application Scientist – ddPCR, NGC and qPCR, Tara Ellison, PhD, Senior Field Application Scientist

Date: June 17, 2020
Time: 9 AM, U.S. Pacific time

• Robust methodology for viral titer using ddPCR
• Precise copy number determination & improved confidence in acceptance criteria
• Enhance your throughput and minimize hands-on time
• Learn how ddPCR is used in other key applications

Carbohydrates are among the most important components of foods, providing energy as well as flavor, texture, and other physical properties. Identification and quantification of carbohydrates in food is commonly performed using high-performance liquid chromatography. Bio-Rad Aminex Ion Exchange Resins have become the industry standard for carbohydrate and organic acid analysis.

Successful chimeric antigen receptor- (CAR-) T cell therapy requires a target antigen that is unique to cancer cells. But what happens when there are no unique antigens? Researchers at Columbia University Medical Center addressed this problem by replacing healthy non-target cells with genetically modified versions lacking the CAR-T cell target. Their results, published in PNAS, may provide a new avenue for treatment of some types of cancer.